Organon (OGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of ten director nominees for the board, each recommended for approval.
Advisory approval of executive compensation for named executive officers is on the agenda.
Proposal to amend and restate the 2021 Incentive Stock Plan is up for shareholder approval.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 is included.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Ten director nominees are presented for election, including individuals with medical, executive, and governance backgrounds.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.
An amendment and restatement of the 2021 Incentive Stock Plan is proposed for approval.
Latest events from Organon
- Net income rose 68% to $146 million on $1.46 billion revenue, with a pending merger and remediation.OGN
Q1 20264 May 2026 - Organon and Sun Pharma announce a merger with strong employee protections and a pending shareholder vote.OGN
Proxy filing30 Apr 2026 - Pending merger with Sun Pharma and Q1 2026 revenue decline highlight key developments.OGN
Proxy filing30 Apr 2026 - Definitive agreement for acquisition by Sun Pharma; shareholder vote and leadership continuity planned.OGN
Proxy filing27 Apr 2026 - Board approves Sun Pharma acquisition, citing value, mission, and continuity; shareholder vote pending.OGN
Proxy filing27 Apr 2026 - Organon to be acquired by Sun Pharma for $11.75Bn in a cash deal at a 103% premium.OGN
Proxy filing27 Apr 2026 - Sun Pharma to acquire Organon for $14/share in cash, creating a top 25 global pharma company.OGN
Proxy filing27 Apr 2026 - Shareholders to vote on directors, executive pay, incentive plan, and auditor amid strong governance.OGN
Proxy filing24 Apr 2026 - 2025 revenue fell 3% to $6.2B; 2026 outlook is flat with margin and policy headwinds.OGN
Q4 202512 Feb 2026